A new concept in the pharmacology of neuroprotection

Journal of Molecular Neuroscience

Volumn 14, Issue 1-2, 2000, Pages 61-68

  Gozes, Illana ^a   Brenneman, Douglas E ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Activity dependent; ADNE; Femtomolar; Neuroprotection; VIP

Indexed keywords

NEUROTROPHIC FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; ARTICLE; HORMONE ACTION; HUMAN; NEUROCHEMISTRY; NEUROENDOCRINOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN;

ANIMALIA;

EID: 0034129883     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:14:1-2:061     Document Type: Article

References (37)

1. Agoston D. V., Eiden L. E., Brenneman D. E., and Gozes I. (1991) Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. Mol. Brain Res. 10, 235-240.
2. Andersson H., Wetmore C., Lindqvist E., Luthman J., and Olson L. (1997) Trimethyltin exposure in the rat induces delayed changes in brain-derived neurotrophic factor, fos and heat shock protein 70. Neurotoxicology 18, 147-159.
3. Arimura A., Somogyvari-Vigh A., Weill C., Fiore R. C., Tatsuno I., Bay V., and Brenneman D. E. (1994) PACAP functions as a neurotrophic factor. Ann. NY Acad. Sci. 739, 228-243
4. Ashur-Fabian O., Giladi E., Brenneman D. E., and Gozes I. (1997) Identification of VIP/PACAP receptors on astrocytes using antisense oligodeoxynucleotides. J. Mol. Neurosci. 9, 211-222.
5. Bassan M., Zamostiano R., Davidson A., Wollman Y., Pitman J., Hauser J., et al. (1998) The identification of secreted heat shock 60 (hsp60)-like protein from rat glial cells and a human neuroblastoma cell line. Neurosci. Lett. 250, 37-40.
6. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283-1293.
7. Brenneman D. E. and Gozes I. (1996) A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97, 2299-2307.
8. Brenneman D. E., Hill J. M., and Gozes I. (1998a) Vasoactive intestinal peptide in the central nervous system, Chapter 57, in Psychopharmacology on CD ROM (Watson, S. J., ed.), Lippincott Williams & Wilkins, Baltimore, MD.
9. Brenneman D. E., Hauser J., Neale E., Rubinraut S., Fridkin M., Davidson A., and Gozes I. (1998b) Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 285, 619-627.
10. Dibbern D. A., Glazner G. W., Gozes I., Brenneman D. E., and Hill J. M. (1997) Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J. Clin. Invest. 99, 2837-2841.
11. Festoff B. W., Nelson P. G., Brenneman D. E. (1996) Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting neurotrophic serpin, protease nexin I. J. Neurobiol. 30, 255-266.
12. Ghosh A., Carnahan J., and Greenberg M. E. (1994) Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263, 1618-1623.
13. Gozes I. and Brenneman D. E. (1989) VIP molecular biology and neurobiological function. Mol. Neurobiol. 3, 201-236.
14. Gozes I. and Brenneman D. E. (1996) Activity-dependent neurotrophic factor (ADNF): an extracellular neuroprotective chaperonin? J. Mol. Neurosci. 7, 235-244.
15. Gozes I., Davidson A., Gozes Y., Mascolo R., Barth R., Warren D., et al. (1997a) Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Dev. Brain Res. 99, 167-175.
16. Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., and Giladi E. (1997b) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimers disease. J. Neurobiol. 33, 329-342.
17. Gozes I., Perl O., Giladi E., Davidson A., Ashur-Fabian O., Rubinraut S., and Fridkin M. (1999) Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. USA 96, 4143-4148.
18. Gressens P., Marret S., Hill J. M., Brenneman D. E., Gozes I., Fridkin M., and Evrard P. (1997) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100, 390-397.
19. Guo Q., Sebastian L., Sopher B. L., Miller M. W., Glazner G. W., Ware C. B., et al. (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. USA 96, 4125-4130.
20. Harmar A. J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J. R., et al. (1998) International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacal. Rev. 50, 265-270.
21. Hashimoto H., Nogi H., Mori K., Ohishi H., Shigemoto R., Yamamoto K., et al. (1996) Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J. Comp. Neurol. 371, 567-577.
22. Hashimoto H., Ogawa N., Hagihara N., Yamamoto K., Imanishi K., Nogi H., et al. (1997) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 52, 128-135.
23. Khan I., Wallin R., Gupta R. S., and Kammer G. M. (1998) Protein kinase A-catalyzedphosphorylation of heat shock protein 60 chaperone regulates its attachment to histone 2B in the T lymphocyte plasma membrane. Proc. Natl. Acad. Sci. USA 95, 10,425-10,430.
24. Krajnak K., Kashon M. L., Rosewell K. L., and Wise P. M. (1998) Aging alters the rhythmic expression of vasoactive intestinal polypeptide mRNA but not arginine vasopressin mRNA in the suprachiasmatic nuclei of female rats. J. Neurosci. 18, 4767-4774.
25. Krieglstein K., Henheik P., Farkas L., Jaszai J., Galter D., Krohn K., and Unsicker K. (1998) Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J. Neurosci. 18, 9822-9834.
26. Levi-Montalcini R., Caramia F., and Angeletti P. U. (1969) Alterations in the fine structure of nucleoli in sympathetic neurons following NGF-antiserum treatment. Brain Res. 12, 54-73.
27. Maimone D., Cioni C., Rosa S., Macchia G., Aloisi F., and Annunziata P. (1993) Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J. Neuroimmunol. 47, 73-82.
28. Mohney R. P. and Zigmond R. E. (1998) Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury. J. Neurosci. 18, 5285-5293.
29. Paspalas C. D. and Papadopoulos G. C. (1998) Ultrastructural evidence for combined action of noradrenaline and vasoactive intestinal polypeptide upon neurons, astrocytes, and blood vessels of the rat cerebral cortex. Brain Res. Bull. 45, 247-259.
30. Pellegri G., Magistretti P. J., and Martin J. L. (1998) VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur. J. Neurosci. 10, 272-280.
31. Said S. I. (1996) Molecules that protect: the defense of neurons and other cells. J. Clin. Invest. 97, 2163-2164.
32. Said S. I. and Mutt V. (1972) Isolation from porcine intestinal wall of a vasoactive octacoaspeptide related to secretin and to glucagon. Eur. J. Biochem. 28, 199-204.
33. Servidei T., Aoki Y., Lewis S. E., Symes A., Fink J. S., and Reeves S. A. (1998) Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2. J. Biol. Chem. 273, 6233-6241.
34. Shen K. F. and Crain S. M. (1992) Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid 'dependence' without tolerance. Brain Res. 597, 74-83.
35. Zafra F., Hengerer B., Leibrock J., Thoenen H., and Lindholm D. (1990) Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J. 9, 3545-3550.
36. Zamostiano R., Pinhasov A., Bassan M., Perl O., Steingart R. A., Atlas R., et al. (1999) A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci. Lett. 264, 9-12.
37. Zupan V., Hill J. M., Brenneman D. E., Gozes I., Fridkin M., Robberecht P., et al. (1998) Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J. Neurochem. 70, 2165-2173.